vs
Side-by-side financial comparison of TECOGEN INC. (TGEN) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $5.3M, roughly 1.0× TECOGEN INC.). TECOGEN INC. runs the higher net margin — -75.1% vs -507.8%, a 432.7% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -12.5%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -7.3%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
TGEN vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $5.5M |
| Net Profit | $-4.0M | $-27.9M |
| Gross Margin | 36.8% | — |
| Operating Margin | -77.8% | -516.0% |
| Net Margin | -75.1% | -507.8% |
| Revenue YoY | -12.5% | 171.3% |
| Net Profit YoY | -236.7% | -48.3% |
| EPS (diluted) | $-0.14 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3M | $5.5M | ||
| Q3 25 | $7.2M | $0 | ||
| Q2 25 | $7.3M | $2.0M | ||
| Q1 25 | $7.3M | $2.3M | ||
| Q4 24 | $6.1M | $2.0M | ||
| Q3 24 | $5.6M | $1.8M | ||
| Q2 24 | $4.7M | $1.1M | ||
| Q1 24 | $6.2M | $3.4M |
| Q4 25 | $-4.0M | $-27.9M | ||
| Q3 25 | $-2.1M | $-32.7M | ||
| Q2 25 | $-1.5M | $-26.9M | ||
| Q1 25 | $-659.9K | $-21.5M | ||
| Q4 24 | $-1.2M | $-18.8M | ||
| Q3 24 | $-930.4K | $-25.5M | ||
| Q2 24 | $-1.5M | $-20.9M | ||
| Q1 24 | $-1.1M | $-24.1M |
| Q4 25 | 36.8% | — | ||
| Q3 25 | 30.4% | — | ||
| Q2 25 | 33.8% | — | ||
| Q1 25 | 44.3% | — | ||
| Q4 24 | 45.0% | — | ||
| Q3 24 | 44.1% | — | ||
| Q2 24 | 44.0% | — | ||
| Q1 24 | 41.6% | — |
| Q4 25 | -77.8% | -516.0% | ||
| Q3 25 | -29.2% | — | ||
| Q2 25 | -19.4% | -1347.1% | ||
| Q1 25 | -8.2% | -930.5% | ||
| Q4 24 | -18.7% | -985.8% | ||
| Q3 24 | -15.5% | -1448.4% | ||
| Q2 24 | -31.2% | -1915.4% | ||
| Q1 24 | -17.0% | -713.3% |
| Q4 25 | -75.1% | -507.8% | ||
| Q3 25 | -29.7% | — | ||
| Q2 25 | -20.1% | -1353.6% | ||
| Q1 25 | -9.1% | -935.2% | ||
| Q4 24 | -19.5% | -929.0% | ||
| Q3 24 | -16.5% | -1427.5% | ||
| Q2 24 | -32.5% | -1882.0% | ||
| Q1 24 | -17.9% | -705.4% |
| Q4 25 | $-0.14 | $-0.08 | ||
| Q3 25 | $-0.07 | $-0.09 | ||
| Q2 25 | $-0.06 | $-0.09 | ||
| Q1 25 | $-0.03 | $-0.08 | ||
| Q4 24 | $-0.05 | $-0.07 | ||
| Q3 24 | $-0.04 | $-0.10 | ||
| Q2 24 | $-0.06 | $-0.09 | ||
| Q1 24 | $-0.04 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.4M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $21.6M | $246.9M |
| Total Assets | $37.0M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.4M | $319.8M | ||
| Q3 25 | $15.3M | $297.3M | ||
| Q2 25 | $1.6M | $312.8M | ||
| Q1 25 | $4.1M | $116.6M | ||
| Q4 24 | $5.4M | $139.0M | ||
| Q3 24 | $1.3M | $157.7M | ||
| Q2 24 | $841.9K | $172.7M | ||
| Q1 24 | $1.5M | $124.0M |
| Q4 25 | $21.6M | $246.9M | ||
| Q3 25 | $25.5M | $219.0M | ||
| Q2 25 | $9.1M | $248.7M | ||
| Q1 25 | $9.6M | $55.1M | ||
| Q4 24 | $10.2M | $71.5M | ||
| Q3 24 | $11.3M | $88.8M | ||
| Q2 24 | $12.2M | $108.9M | ||
| Q1 24 | $13.7M | $53.8M |
| Q4 25 | $37.0M | $343.3M | ||
| Q3 25 | $41.5M | $316.6M | ||
| Q2 25 | $28.4M | $333.3M | ||
| Q1 25 | $29.7M | $138.4M | ||
| Q4 24 | $31.1M | $160.4M | ||
| Q3 24 | $27.5M | $180.2M | ||
| Q2 24 | $27.2M | $200.4M | ||
| Q1 24 | $28.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-26.7M |
| Free Cash FlowOCF − Capex | $-2.6M | — |
| FCF MarginFCF / Revenue | -49.3% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $-26.7M | ||
| Q3 25 | $-3.6M | $-24.2M | ||
| Q2 25 | $-2.6M | $-20.2M | ||
| Q1 25 | $-1.2M | $-22.0M | ||
| Q4 24 | $4.2M | $-18.3M | ||
| Q3 24 | $-207.3K | $-21.6M | ||
| Q2 24 | $-157.9K | $-21.5M | ||
| Q1 24 | $248.2K | $-19.8M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-3.6M | $-24.3M | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-1.3M | — | ||
| Q4 24 | $4.0M | $-18.3M | ||
| Q3 24 | $-489.6K | $-21.6M | ||
| Q2 24 | $-609.6K | $-21.7M | ||
| Q1 24 | $143.3K | $-19.9M |
| Q4 25 | -49.3% | — | ||
| Q3 25 | -50.6% | — | ||
| Q2 25 | -37.7% | — | ||
| Q1 25 | -17.9% | — | ||
| Q4 24 | 66.6% | -905.5% | ||
| Q3 24 | -8.7% | -1210.9% | ||
| Q2 24 | -12.9% | -1951.9% | ||
| Q1 24 | 2.3% | -584.5% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 2.1% | 0.1% | ||
| Q3 24 | 5.0% | 2.0% | ||
| Q2 24 | 9.6% | 18.1% | ||
| Q1 24 | 1.7% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TGEN
| Installation Services | $4.5M | 84% |
| Products Segment | $460.5K | 9% |
| Other | $394.7K | 7% |
TSHA
Segment breakdown not available.
